Chao Gao1; Rutao Wang1; Faisal Sharif2; Kuniaki Takahashi3; Masafumi Ono4; Hironori Hara4; Mariusz Tomaniak5; Hideyuki Kawashima4; Rodrigo Modolo6; Robert-Jan van Geuns7; Davide Capodanno8; Robert Byrne9; William Wijns2; Yoshinobu Onuma2; Patrick W Serruys10, ;
1. Department of Cardiology. Xijing hospital, Xi’an, China; Department of Cardiology, Radboud University, Nijmegen, Netherlands; Department of Cardiology, National University of Ireland Galway, Galway, Ireland 2. Department of Cardiology, National University of Ireland Galway, Galway, Ireland 3. Department of Cardiology, Amsterdam University Medical Center, Amsterdam, Netherlands 4. Department of Cardiology, National University of Ireland Galway, Galway, Ireland; Department of Cardiology, Amsterdam University Medical Center, Amsterdam, Netherlands 5. Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands 6. Department of Internal Medicine. Cardiology division. University of Campinas (UNICAMP), Campinas, SP, Brazil. 7. Department of Cardiology, Radboud University, Nijmegen, Netherlands 8. Division of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy 9. Deutsches Herzzentrum München, Technische Universität München, Munich, Germany 10. Department of Cardiology, National University of Ireland Galway, Galway, Ireland; NHLI, Imperial College London, London, United Kingdom, United Kingdom
As a public service to our readership, this article - peer reviewed by the Editors of EuroIntervention - has been published immediately upon acceptance as it was received. The content of this article is the sole responsibility of the authors, and not that of the journal or its publishers.
Please note that supplementary movies are not available online at this stage. Once a paper is published in its edited and formatted form, it will be accompanied online by any supplementary movies.
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Since nearly 30 years ago, the antiplatelet therapy was introduced and remains the cornerstone of Percutaneous Coronary Interventions (PCI). In the year of 2019, results of several pivotal trials seemed to herald a new era of antiplatelet therapy -the era of aspirin-free strategy. In the same year, the debates of the optimal revascularization strategy for patients with left main or multivessel disease were reignited; the attempt of early infusing alteplase after coronary reperfusion to reduce microvascular obstruction was disproven, and the result of the ISCHEMIA trial showed no advantage of routine invasive treatment in patients with chronic coronary syndrome (CCS).
New publications and research related to coronary interventional practice have emerged and will be highlighted in this review, which comprises the prominent interventional cardiology publications from the high-impact journals: New England Journal of Medicine, Lancet, JAMA (including JAMA Cardiology), European Heart Journal, Journal of the American College of Cardiology, Circulation, JACC Cardiovascular Interventions, Circulation Cardiovascular Interventions, and EuroIntervention. The focus of this article is to summarize the findings of the pivotal trials (illustrated in Figure 1) and their impact on clinical practice.